Paris, France – 22 June 2015 - Seventure, one of Europe’s leaders in financing innovation, today announced the appointment of Danilo Casadei Massari and Dr Thomas Werner to its Health for Life CapitalTM fund Investment Committee. They are two very experienced figures in the international life science sector with outstanding track records which will strengthen Seventure’s team.
Danilo Casadei Massari has over 30 years of senior management experience in the pharmaceutical field and is a highly successful serial entrepreneur. Most recently he was a founder and President of CM&D Pharma Ltd, a medical food company sold to Nestle Health Science in 2011. Prior appointments include VP Corporate Development at Madaus Group, CEO of Madaus Italy, and Board positions at Fidia Farmaceutici SpA and Sinclair Pharmaceuticals Ltd. He is currently a Director on the boards of two companies in the US (Prismic Pharmaceuticals Inc and Clinical Information Network Inc) where he is a founding member, and two in Italy (Difass International Srl and InterAlia Srl). Danilo is an expert in start-ups and co-ventures in the pharmaceutical sector.
Dr Thomas Werner is an independent highly experienced industry expert for several Venture Capital and Private Equity companies in the healthcare and nutrition sectors. He acts as executive and non-executive member and chairman for numerous boards, including Basilea Pharmaceutica, Riemser Pharma, Skyepharma and BSN medical. He was also involved as Chairman of CM&D Pharma and PharmaSwiss at the time of their exit to Nestle and Valeant. He was also a member of the Board of SuppreMol until their recent acquisition by Baxter. Before then, he was a managing director at Glaxo SmithKline Germany and a Senior Vice President of GSK plc and a managing director at Bristol-Myers Squibb Germany.
Isabelle de Cremoux, President and CEO at Seventure Partners, said: “With the recent closing of the Health for Life CapitalTM fund, the largest fund worldwide that focusses primarily on microbiome, we are looking for new investment opportunities. Danilo and Thomas’ collective international experience in the pharma, healthcare and nutrition sectors will help considerably in identifying potential new investments and advising us in our strategic approach of this booming field. We welcome them to the team.”
About Health for Life CapitalTM
In December 2013, Seventure launched Health for Life CapitalTM, the first venture capital fund focused on investment in the microbiome and nutrition space. Europe is the primary focus of the fund, but it will expand internationally if strategic opportunities arise. The €120m fund attracted strategic investments from prestigious organisations including Danone, Tereos, Tornier and Lesaffre, as well as financial institutions. Health for Life CapitalTM is managed by Seventure’s life sciences team.
About Seventure Partners
As one of the leading venture capital firms in Europe, Seventure manages more than €500m. Since 1997, the firm has been investing in innovative businesses with high growth potential; in Digital Technologies in France and Germany, and in Life Sciences across Europe.
In Life Sciences, Seventure’s four preferred sectors are:
The firm will also look at companies or technologies in diagnostics, biomarkers, drug delivery systems, and services.
A typical investment by Seventure ranges from €500k to €10m per round and up to €20m per company, from early to later stage.
Seventure is a subsidiary of Natixis, the corporate investment management and financial services arm of
Groupe BPCE, the second-largest French bank.
For more information, please visit: www.seventure.com
Issued for and on behalf of Seventure by Instinctif Partners.
For more information please contact: firstname.lastname@example.org
Melanie Toyne-SewellManaging Partner